Dynavax Co-founder Takes Long View on Vaccine Development
Xconomy
DECEMBER 4, 2017
The reaction on Wall Street was a little anticlimactic after the FDA approved a new hepatitis B vaccine last month for Berkeley, CA-based Dynavax Technologies (NASDAQ: DVAX ). For Dennis Carson, however, the FDA announcement represented the culmination of a scientific odyssey that took 21 years. Many investors sold stock on the news.
Let's personalize your content